Cardiac Abnormalities in Acromegaly Patients: A Cardiac Magnetic Resonance Study
Table 3
Risk factors related to myocardial hypertrophy, systolic function and myocardial fibrosis.
LVH+ (n = 16)
LVH− (n = 45)
IVSH+ (n = 17)
IVSH− (n = 44)
LVSD+ (n = 5)
LVSD− (n = 56)
RVSD+ (n = 6)
RVSD− (n = 55)
MCF+ (n = 9)
MCF− (n = 52)
GH (ng/ml)
56.1 ± 72.6
33.0 ± 38.5
47.5 ± 68.0
35.8 ± 41.7
6.0 ± 2.3
42.0 ± 51.3
10.7 ± 8.1
42.2 ± 51.8
52.4 ± 81.8
36.8 ± 43.2
GH nadir (ng/ml)
47.2 ± 65.2
21.4 ± 26.6
40.0 ± 62.3
23.7 ± 29.4
5.0 ± 1.9
30.3 ± 42.6
9.2 ± 7.7
30.3 ± 43.0
44.1 ± 72.6
25.5 ± 33.7
IGF-1 (ng/ml)
887.9 ± 249.0
899.5 ± 258.3
912.7 ± 299.5
890.2 ± 237.5
855.2 ± 420.0
900.1 ± 239.4
963.8 ± 381.5
889.1 ± 240.0
859.0 ± 214.7
902.9 ± 261.3
Age (years)
47.7 ± 12.5
41.2 ± 13.6
50.8 ± 14.4
39.9 ± 12.0
58.0 ± 8.0
41.5 ± 13.0
50.0 ± 10.8
42.2 ± 13.7
48.8 ± 9.9
42.0 ± 14.0
Body mass index (kg/m2)
28.2 ± 3.6
25.4 ± 3.6
28.0 ± 3.7
25.4 ± 3.6
28.7 ± 3.1
25.9 ± 3.8
31.3 ± 5.8
25.6 ± 3.1
28.7 ± 3.3
25.7 ± 3.7
Disease duration (months)
102 ± 61.7
70.1 ± 53.6
93.9 ± 50.1
72.5 ± 59.0
81.6 ± 41.0
78.2 ± 58.5
144.0 ± 56.3
71.3 ± 52.8
101.3 ± 72.3
74.5 ± 53.9
Arterial hypertension (yes/no)/(%)
6/10, 37.5%
5/40, 11.1%
6/11, 35.3%
5/39, 11.4%
3/2, 60.0%
8/48, 14.3%
4/2, 66.7%
7/48, 12.7%
4/5, 44.4%
7/45, 13.5%
Diabetes mellitus (yes/no)/(%)
4/12, 25.0%
4/41, 8.9%
4/13, 23.5%
4/40, 9.1%
2/3, 40.0%
6/50, 10.7%
3/3, 50.0%
5/50, 9.1%
1/8, 11.1%
7/45, 13.5%
Hyperlipemia (yes/no)/(%)
1/15, 6.3%
7/38, 15.6%
2/15, 11.8%
6/38, 13.6%
0/5, 0.0%
8/48, 14.3
0/6, 0.0%
8/47, 14.5%
1/8, 11.1%
7/45, 13.5%
Smoking habit (yes/no)/(%)
6/10, 37.5%
6/39, 13.3%
6/11, 35.3%
6/38, 13.6%
2/3, 40.0%
10/46, 17.9%
3/3, 50.0%
9/46, 16.4%
3/6, 33.3%
9/43, 17.3%
GH, growth hormone; IGF-1, insulin-like growth factor 1; LVH, left ventricular hypertrophy; IVSH, interventricular septum hypertrophy; LVSD, left ventricular systolic dysfunction; RVSD, right ventricular systolic dysfunction; MCF, myocardial fibrosis. Values are presented as frequencies (%) and the mean ± standard deviation. It means the difference between male and female patients is significant ().
